By Joel Rizzo
(PR Newswire)MiMedx Group Inc. (NASDAQ:MDXG) the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced that it has received notice from the Department of Justice that it has declined at this time to intervene in the qui tam action that gave rise to the issuance of a subpoena to MiMedx from the Department of Health and Human Services, Office of Inspector General (“OIG”) a few months ago.
MiMedx has extensively cooperated with the government in responding to the subpoena and has provided in excess of 100,000 lines of electronic data to the OIG. The Company took the initiative to expedite the investigative process and rapidly produced responsive documents needed by the OIG to conduct its investigation.
Parker H. Petit, Chairman and CEO, said, “We are pleased that the government has declined at this time to intervene in the qui tam action. We appreciate the expediency, professionalism and thoroughness with which the OIG conducted its investigation. We will continue to cooperate with any other requests by the government, and we are confident that we have not engaged in wrongdoing which would support a qui tam action. This inquiry has certainly allowed us to comprehensively evaluate all aspects of our compliance programs and reaffirm the effectiveness of our policies and standards. We are pleased that we have continually maintained a culture of compliance and diligently stressed adherence within our organization. We welcome the opportunity for our industry practices to be put under the microscope. Our experience needs to serve as a catalyst for all of our industry to ensure all practices are beyond reproach. All of our industry organizations owe this to the countless patients, their physicians and their health plans that benefit from our respective products and services.”
